Polyunsaturated fatty acids and gliomas: A critical review of experimental, clinical, and epidemiologic data

Nutrition

Volumn 30, Issue 10, 2014, Pages 1104-1109

  Sandrone, Silvana Silvia ^a,b   Repossi, Gaston ^a,c   Candolfi, Marianela ^d,e   Eynard, Aldo Renato ^a,e  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b Hospital Rawson   (Argentina)

^c Universidad Nacional de La Rioja   (Argentina)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^e UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

Central nervous system tumors; Essential fatty acids; Glioma treatment; Polyunsaturated fatty acids

Indexed keywords

DOCOSAHEXAENOIC ACID; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; POLYUNSATURATED FATTY ACID; ESSENTIAL FATTY ACID; LINOLEOYL COENZYME A DESATURASE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CYTOTOXICITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FATTY ACID ANALYSIS; FATTY ACID METABOLISM; GLIOMA; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SYNDROME DELINEATION; TREATMENT RESPONSE; ANIMAL; DIET; GLIOBLASTOMA; METABOLISM;

RODENTIA;

ANIMALS; DIET; FATTY ACIDS, ESSENTIAL; GLIOBLASTOMA; GLIOMA; HUMANS; LINOLEOYL-COA DESATURASE;

EID: 84924811185     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2014.01.009     Document Type: Review

References (53)

1. Comba A., Lin Y.-H., Eynard A.R., Valentich M.A., Fernandez-Zapico M.E., Pasqualini M.E. Basic aspects of tumor cell fatty acid-regulated signaling and transcription factors. Cancer Metastasis Rev 2011, 30:325-342.
2. Das U.N. Essential fatty acids-a review. Curr Pharm Biotechnol 2006, 7:467-482.
3. Das U.N. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J 2006, 1:420-439.
4. Eynard A.R. Potential of essential fatty acids as natural therapeutic products for human tumors. Nutrition 2003, 19:386-388.
5. Das U.N., Prasad V.V., Reddy D.R. Local application of gamma-linolenic acid in the treatment of human gliomas. Cancer Lett 1995, 94:147-155.
6. Sangeetha P., Das U.N. Cytotoxic action of cis-unsaturated fatty acids on human cervical carcinoma (HeLa) cells: relationship to free radicals and lipid peroxidation and its modulation by calmodulin antagonists. Cancer Lett 1992, 63:189-198.
7. Das U.N. Tumoricidal action of cis-unsaturated fatty acids and its relationship to free radicals and lipid peroxidation. Cancer Lett 1991, 50:235-243.
8. Leaver H.A., Rizzo M.T., Whittle I.R. Antitumour actions of highly unsaturated fatty acids: cell signalling and apoptosis. Prostaglandins Leukot Essent Fatty Acids 2002, 66:1-3.
9. Kyritsis A.P., Bondy M.L., Rao J.S., Sioka C. Inherited predisposition to glioma. Neuro Oncol 2010, 12:104-113.
10. Kyritsis A.P., Bondy M.L., Levin V.A. Modulation of glioma risk and progression by dietary nutrients and antiinflammatory agents. Nutr Cancer 2011, 63:174-184.
11. Burger P.C., Scheithauer B.W. Tumors of neuroglia and choroid plexus. Tumors of the central nervous system. Afip atlas of tumor pathology 2007, 33-177. American Registry of Pathology-Armed Forces Institute of Pathology, Washington, DC. S.G. Silverberg (Ed.).
12. Kleihues P., Louis D.N., Wiestler O.D., Burger P.C., Scheithauer B.W. WHO grading of tumours of the central nervous system. WHO classification of tumours of the central nervous system 2007, 10-11. International Agency for Research on Cancer, Lyon. 4th edition. D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavenee (Eds.).
13. Miller C.R., Perry A. Glioblastoma. Arch Pathol Lab Med 2007, 131:397-406.
14. Crocetti E., Trama A., Stiller C., Caldarella A., Soffietti R., Jaal J., et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer 2012, 48:1532-1542. RARECARE working group.
15. Porter K.R., McCarthy B.J., Freels S., Kim Y., Davis F.G. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol 2010, 12:520-527.
16. Díaz M.P., Osella A.R., Aballay L.R., Muñoz S.E., Lantieri M.J., Butinof M., et al. Cancer incidence pattern in Cordoba, Argentina. Eur J Cancer Prev 2009, 18:259-266.
17. Moreno F. Registro Oncopediátrico Hospitalario Argentino: resultados 2000-2005. Instituto Nacional del Cancer, Buenos Aires.2007.
18. Colman H., Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Arch Neurol 2008, 65:877-883.
19. de Camargo B., de Oliveira Santos M., Rebelo M.S., de Souza Reis R., Ferman S., Noronha C.P., et al. Cancer incidence among children and adolescents in Brazil: first report of 14 population-based cancer registries. Int J Cancer 2010, 126:715-720.
20. McGirt M.J., Chaichana K.L., Attenello F.J., Weingart J.D., Than K., Burger P.C., et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008, 63:700-707.
21. Van den Bent M.J., Afra D., de Witte O., Ben Hassel M., Schraub S., Hoang-Xuan K., et al. Long-term efficacy of early versus delayedradiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005, 366:985-990. EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council.
22. Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005, 64:479-489.
23. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
24. Amberger-Murphy V. Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets 2009, 9:381-390.
25. Hegi M.E., Diserens A.C., Godard S., Dietrich P.Y., Regli L., Ostermann S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10:1871-1874.
26. Pulkkanen K.J., Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol Ther 2005, 12:585-598.
27. Vartak S., Robbins M.E., Spector A.A. Polyunsaturated fatty acids increase the sensitivity of 36B10 rat astrocytoma cells to radiation-induced cell kill. Lipids 1997, 32:283-292.
28. Vartak S., McCaw R., Davis C.S., Robbins M.E., Spector A.A. Gamma-linolenic acid (GLA) is cytotoxic to 36B10 malignant rat astrocytoma cells but not to 'normal' rat astrocytes. Br J Cancer 1998, 77:1612-1620.
29. Preuss M., Girnun G.D., Darby C.J., Khoo N., Spector A.A., Robbins M.E. Role of antioxidant enzyme expression in the selective cytotoxic response of glioma cells to gamma-linolenic acid supplementation. Free Radic Biol Med 2000, 28:1143-1156.
30. Leaver H.A., Williams J.R., Craig S.R., Gregor A., Ironside J.W., Whittle I.R., et al. Network analysis of arachidonic acid pathophysiology in human phagocytes and primary brain tumors. Ann NY Acad Sci 1997, 832:200-214.
31. Leaver H.A., Williams J.R., Ironside J.W., Miller E.P., Gregor A., Su B.H., et al. Dynamics of reactive oxygen intermediate production in human glioma: n-6 essential fatty acid effects. Eur J Clin Invest 1999, 29:220-231.
32. Williams J.R., Leaver H.A., Ironside J.W., Miller E.P., Whittle I.R., Gregor A. Apoptosis in human primary brain tumours: actions of arachidonic acid. Prostaglandins Leukot Essent Fatty Acids 1998, 58:193-200.
33. Bell H.S., Wharton S.B., Leaver H.A., Whittle I.R. Effects of N-6 essential fatty acids on glioma invasion and growth: experimental studies with glioma spheroids in collagen gels. J Neurosurg 1999, 91:989-996.
34. Leaver H.A., Williams J.R., Smith C., Whittle I.R. Intracellular oxidation by human glioma cell populations: effect of arachidonic acid. Prostaglandins Leukot Essent Fatty Acids 2004, 70:449-453.
35. Ramos K.L., Colquhoun A. Protective role of glucose-6-phosphate dehydrogenase activity in the metabolic response of C6 rat glioma cells to polyunsaturated fatty acid exposure. Glia 2003, 43:149-166.
36. Benadiba M., Miyake J.A., Colquhoun A. Gamma-linolenic acid alters Ku80, E2F1, and bax expression and induces micronucleus formation in C6 glioma cells invitro. IUBMB Life 2009, 61:244-251.
37. Ribeiro G., Benadiba M., de Oliveira Silva D., Colquhoun A. The novel ruthenium-gamma-linolenic complex [Ru(2)(aGLA)(4)Cl] inhibits C6 rat glioma cell proliferation and induces changes in mitochondrial membrane potential, increased reactive oxygen species generation and apoptosis invitro. Cell Biochem Funct 2010, 28:15-23.
38. Faragó N., Fehér L.Z., Kitajka K., Das U.N., Puskás L.G. MicroRNA profile of polyunsaturated fatty acid treated glioma cells reveal apoptosis-specific expression changes. Lipids Health Dis 2011, 10:173.
39. Leaver H.A., Wharton S., Thomson D., Bell H., Whittle I.R. Comparative pharmacodynamics and bioavailability of a novel anti-tumour agent, gamma linolenic acid, in three glioma models: effects on tumor biomass, apoptosis and normal neuronal tissue histology. Cancer Detect Prevent 1998, 27:629.
40. Leaver H.A., Bell H.S., Rizzo M.T., Ironside J.W., Gregor A., Wharton S.B., et al. Antitumour and pro-apoptotic actions of highly unsaturated fatty acids in glioma. Prostaglandins Leukot Essent Fatty Acids 2002, 66:19-29.
41. Whittle I.R., Macarthur D.C., Malcolm G.P., Li M., Washington K., Ironside J.W. Can experimental models of rodent implantation glioma be improved? A study of pure and mixed glioma cell line tumours. J Neurooncol 1998, 36:231-242.
42. Leaver H.A., Wharton S.B., Bell H.S., Leaver-Yap I.M., Whittle I.R. Highly unsaturated fatty acid induced tumour regression in glioma pharmacodynamics and bioavailability of gamma linolenic acid in an implantation glioma model: effects on tumour biomass, apoptosis and neuronal tissue histology. Prostaglandins Leukot Essent Fatty Acids 2002, 67:283-292.
43. Miyake J.A., Benadiba M., Colquhoun A. Gamma-linolenic acid inhibits both tumour cell cycle progression and angiogenesis in the orthotopic C6 glioma model through changes in VEGF, Flt1, ERK1/2, MMP2, cyclin D1, pRb, p53 and p27 protein expression. Lipids Health Dis 2009, 8:8.
44. Das U.N. Tumoricidal action of cis-unsaturated fatty acids and their relationship to free radicals and lipid peroxidation. Cancer Lett 1991, 56:235-243.
45. Naidu M.R., Das U.N., Kishan A. Intratumoral gamma-linoleic acid therapy of human gliomas. Prostaglandins Leukot Essent Fatty Acids 1992, 45:181-184.
46. Reddy D.R., Prassad V.S., Das U.N. Intratumoural injection of gamma leinolenic acid in malignant gliomas. J Clin Neurosci 1998, 5:36-39.
47. Bakshi A., Mukherjee D., Bakshi A., Banerji A.K., Das U.N. Gamma-linolenic acid therapy of human gliomas. Nutrition 2003, 19:305-309.
48. Das U.N. From bench to the clinic: gamma-linolenic acid therapy of human gliomas. Prostaglandins Leukot Essent Fatty Acids 2004, 70:539-552.
49. Das U.N. Gamma-linolenic acid therapy of human glioma-a review of invitro, invivo, and clinical studies. Med Sci Monit 2007, 13:119-131.
50. Martin D.D., Robbins M.E., Spector A.A., Wen B.C., Hussey D.H. The fatty acid composition of human gliomas differs from that found in nonmalignant brain tissue. Lipids 1996, 31:1283-1288.
51. Nasrollahzadeh J., Siassi F., Doosti M., Eshraghian M.R., Shokri F., Modarressi M.H., et al. The influence of feeding linoleic, gamma-linolenic and docosahexaenoic acid rich oils on rat brain tumor fatty acids composition and fatty acid binding protein 7 mRNA expression. Lipids Health Dis 2008, 7:45-47.
52. Zajdel A., Wilczok A., Latocha M., Dzierzewicz Z. Effect of polyunsaturated fatty acids on doxorubicin cytotoxity in glioma calls invitro. Adv Clin Exp Med 2010, 19:481-487.
53. Katz R., Hamilton J.A., Spector A.A., Moore S.A., Moser H.W., Noetzel M.J., et al. Brain uptake and utilization of fatty acids: recommendations for future research. J Mol Neurosci 2001, 16:333-335.